The FDA decision on Alnylam Pharmaceuticals Inc.’s (ALNY) Onpattro for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis is due on October 8, 2023.Last month, an FDA panel recommended approval of the drug for the expanded use.The regulatory agency usually follows the recommendations of its panels although it is not required to do so.Onpattro, an intravenously administered RNAi therapeutic, is already approved for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.The global net product revenues for Onpattro in the second quarter of 2023 was $91 million, down 40% from the year-ago quarter.ALNY closed Wednesday’s trading at $169.17.